Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States.
about
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesProgress in Palliative Care Benefit of Elderly Patients with Non-small Cell Lung CancerPemetrexed versus vinorelbine treatment of advanced non-squamous non-small cell lung cancer in elderly patientsLung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites.Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer.Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba.Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.Safety creatinine clearance level for platinum chemotherapy in lung cancer patientsAge-dependent decline in renal function in patients with lung cancerThe role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancerComparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experienceClinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study.Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians.Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients.Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.[The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer].
P2860
Q26766180-22E4CED2-D001-43AF-A478-4A986CBB4979Q26800146-D723A417-293E-4985-9665-B352BA041703Q33414072-310AF885-0EB8-43A6-BEA4-CB1D03E24587Q34180013-6ECFD7C3-91CB-4CBB-A453-5240ABE89162Q34401471-B238BB55-18A2-4253-88FD-902F16D83AC5Q35043089-1D3E7897-CC08-4BE5-A464-C1D0606AF5F2Q35262406-7EF1A3C5-C0AD-4003-8005-4AA74EC9A3AAQ35849504-EF8E63A6-A596-462A-BFCF-8E37B4ABBB13Q35995470-5C412A55-4133-45EF-AE52-34FF84527291Q36099297-FC3CF446-7F56-4658-BCF3-FB41E252428BQ36142491-88D9B443-C276-4C24-9FD4-F6BD70C54809Q36304283-67AE6230-F069-441E-AB2C-87CF205E6F59Q36374254-8B8E8F88-4553-4176-801B-54B0C5ECC2A7Q36774403-8DFE8D91-08D8-495B-BA30-AAAC98F5E9ECQ37372172-28315A20-1D9E-4629-9609-ECAD0D6A22D4Q37509502-C8B9CBF1-BCED-4BA8-AAAB-C15551661E89Q37701843-EE94BCC6-CE71-4519-87AB-A10E93F98ADAQ38711948-BFC1146D-A0A7-4E0F-8D98-2998E9FE1088Q39251171-E1907F91-A8FA-4261-AF71-C45FEA65632AQ40315977-5207EB9D-8928-4CD3-B294-CAED0E3ACE94Q41043819-EE2E91B3-250E-40B9-ACF3-DCC7605BD394Q41411537-98D8CC29-13D8-4FF7-8B0E-DD2070112042Q43620697-9B0423C8-DB7E-4568-A958-7852681E1D89Q55451743-EBB78A47-7BB3-41BC-9260-400B1FD0DAAA
P2860
Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Trends and predictors of first ...... g cancer in the United States.
@en
Trends and predictors of first ...... g cancer in the United States.
@nl
type
label
Trends and predictors of first ...... g cancer in the United States.
@en
Trends and predictors of first ...... g cancer in the United States.
@nl
prefLabel
Trends and predictors of first ...... g cancer in the United States.
@en
Trends and predictors of first ...... g cancer in the United States.
@nl
P2093
P1433
P1476
Trends and predictors of first ...... g cancer in the United States.
@en
P2093
Craig Earle
David Thompson
Don Buesching
Doug Faries
Joseph Treat
Kathleen Lang
Martin D Marciniak
Michael Stokes
Nathalie Morissette
P304
P356
10.1016/J.LUNGCAN.2008.05.003
P577
2008-07-22T00:00:00Z